Zhang Feng, Meng Weizhe, Tong Bin
Department of Ophthalmology, The People's Hospital of Beizhou, Binzhou, Shandong, China (mainland).
Department of Ophthalmology, The People's Hospital of Binzhou, Binzhou, Shandong, China (mainland).
Med Sci Monit. 2016 Nov 1;22:4139-4145. doi: 10.12659/msm.896975.
BACKGROUND MicroRNA-133b (miR-133b) has been reported to be involved in many diseases, including ovarian cancer and osteosarcoma. Accumulating evidence suggests that miR-133b plays important roles in human disease. In this study, we aimed to investigate the molecular mechanism, including the potential regulator and signaling pathways, of BCL2L2. MATERIAL AND METHODS We first searched the online miRNA database (www.mirdb.org) using the "seed sequence" located within the 3'-UTR of the target gene, and then performed luciferase assay to test the regulatory relationship between miR-133b and BCL2L2. Western blot and real-time PCR were used to determine the expression of BCL2L2 in human samples or cells treated with miRNA mimics or inhibitors. Flow cytometry was conducted to evaluate the apoptosis status of the cells. RESULTS We validated BCL2L2 to be the direct gene using a luciferase reporter assay. We also conducted real-time PCR and Western blot analyses to study the mRNA and protein expression level of BCL2L2 among different groups (control: n=29, cataract: n=33) or cells treated with scramble control, miR-133b mimics, BCL2L2 siRNA, and miR-133b inhibitors, and identified the negative regulatory relationship between miR-133b and BCL2L2. We also conducted experiments to investigate the influence of miR-133b and BCL2L2 on the viability and apoptosis of cells. The results showed that miR-133b positively interfered with the viability of cells, while BCL2L2 negatively interfered with the viability of cells, and that miR-133b inhibited apoptosis while BCL2L2 accelerated apoptosis. CONCLUSIONS BCL2L2 was the virtual target of miR-133b, and we found a negative regulatory relationship between miR-133b and BCL2L2. MiR-133b and BCL2L2 interfered with the viability and apoptosis of cells.
背景 据报道,微小RNA-133b(miR-133b)参与多种疾病,包括卵巢癌和骨肉瘤。越来越多的证据表明,miR-133b在人类疾病中发挥重要作用。在本研究中,我们旨在探究BCL2L2的分子机制,包括潜在的调节因子和信号通路。
材料与方法 我们首先使用位于靶基因3'-UTR内的“种子序列”在在线miRNA数据库(www.mirdb.org)中进行搜索,然后进行荧光素酶测定以检测miR-133b与BCL2L2之间的调节关系。采用蛋白质免疫印迹法和实时定量PCR来测定在经miRNA模拟物或抑制剂处理的人类样本或细胞中BCL2L2的表达。进行流式细胞术以评估细胞的凋亡状态。
结果 我们使用荧光素酶报告基因测定法验证了BCL2L2是直接基因。我们还进行了实时定量PCR和蛋白质免疫印迹分析,以研究不同组(对照组:n = 29,白内障组:n = 33)或经乱序对照、miR-133b模拟物、BCL2L2小干扰RNA和miR-133b抑制剂处理的细胞中BCL2L2的mRNA和蛋白质表达水平,并确定了miR-133b与BCL2L2之间的负调节关系。我们还进行了实验以研究miR-133b和BCL2L2对细胞活力和凋亡的影响。结果表明,miR-133b正向干扰细胞活力,而BCL2L2负向干扰细胞活力,并且miR-133b抑制凋亡,而BCL2L2加速凋亡。
结论 BCL2L2是miR-133b的实际靶标,我们发现miR-133b与BCL2L2之间存在负调节关系。miR-133b和BCL2L2干扰细胞的活力和凋亡。